Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR6 | P46095 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 9/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | STK17B | O94768 | 1/20 | 0.35 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4316443 | 0.86 | BCDIN3D (0.41) | GPR6CYP2D6PKMCYP2C19P2RX7 | |
| SCHEMBL4325799 | 0.82 | GPR6 (0.43) | GPR6CYP2D6PKMCYP2C19P2RX7 | |
| SCHEMBL4311781 | 0.78 | MTOR (0.41) | GPR6CYP2D6PKMCYP2C19 | |
| SCHEMBL4315802 | 0.78 | CCR4 (0.41) | GPR6CYP2D6PKMCYP2C19P2RX7 | |
| SCHEMBL4311911 | 0.77 | CYP2D6 (0.39) | GPR6CYP2D6PKMCYP2C19TRPV1 | |
| SCHEMBL4311880 | 0.76 | GPR6 (0.39) | GPR6 | |
| SCHEMBL4318035 | 0.75 | PDE10A (0.38) | GPR6CYP2D6PKMCYP2C19P2RX7 | |
| SCHEMBL4321562 | 0.75 | IGF1R (0.41) | CYP2D6PKMCYP2C19TRPV1 | |
| SCHEMBL4324500 | 0.74 | GPR6 (0.39) | GPR6 | |
| SCHEMBL4315809 | 0.74 | CCR4 (0.38) | GPR6CYP2D6PKMCYP2C19P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524852-B2 | Bicyclic pyrimidine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-04-28 | — | — | US | disclosed |
| US-20070037834-A1 | Anti-inflammatory; cellular infiltration inhibition modulating activity on thymus and activation-regulated chemokine and macrophage-derived chemokine functions; inhibitory activities against binding of TARC and MDC to T cells; allergic disease, autoimmune disease, transplant, graft rejection | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| EP-1552842-A1 | BICYCLIC PYRIMIDINE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037834-A1 | Anti-inflammatory; cellular infiltration inhibition modulating activity on thymus and activation-regulated chemokine and macrophage-derived chemokine functions; inhibitory activities against binding of TARC and MDC to T cells; allergic disease, autoimmune disease, transplant, graft rejection | CX3CR1, CCL5, CCRL2 | GPR6 552/4885CYP2D6 4256/4885PKM 3746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.